secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2026-04-14T23:59:59+00:00
Accession:  0001651308-26-000008
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

BeOne Medicines reports FY2025 revenue $5.34B, R&D spend $2.15B
---------------------------------------------------------------

- Revenue $5.34B, up 40% YoY; gross margin 87.5% (China 66.6%, ex-China 97.0%)
- R&D total $2.15B, up 10% YoY; largest pipeline: sonrotoclax $176.7M, BRUKINSA $97.6M
- Key product production 6.27M vials, sales 5.99M vials; inventory 2.91M vials at Dec 31, 2025
- U.S. GAAP vs PRC GAAP differences: stock compensation and lease accounting treatments vary

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130826000008/0001651308-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130826000008/bgne-20260414.htm
  HTML page:      https://secwatch.observer/filing/0001651308-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer